Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on November 7, 2016, to report positive clinical data from a Phase Ia/Ib study of its investigational drug CC-31244. The company is developing this oral, pan-genotypic NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C virus (HCV) infection.
Key Financial Metrics
This filing is a Current Report regarding a clinical trial event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The primary material event is the announcement of data from a randomized, double-blind study involving 42 healthy volunteers and 5 HCV genotype 1 (GT1) infected patients. Key results include:
- Antiviral Efficacy: In the 400 mg once-daily dosing arm, CC-31244 demonstrated a substantial and durable antiviral effect with an average HCV RNA viral load decline of 3 log orders by 48 hours post-dosing.
- Durability: The average viral load remained 1.9 log orders below baseline at 6 days post-last dose.
- Safety: No viral breakthrough was observed during the treatment period, and no serious adverse events were reported.
Outlook, Risks, and Management Commentary
Management highlighted that CC-31244 is designed with a high barrier to drug resistance using the company's proprietary structure-based drug discovery technology. However, the filing includes a standard caution that the Company cannot offer assurances that future clinical results will be comparable to the initial data presented.
Investor Verification Checklist
- Verify the full study design and statistical significance of the 3 log order decline in the small patient cohort (n=4 treated).
- Confirm the timeline for the next phase of clinical development or potential partnership discussions.
- Review the company's cash runway and capital requirements in subsequent filings (e.g., 10-Q or 10-K) given the lack of revenue data in this report.
- Monitor for any updates on the safety profile as the study progresses to larger cohorts.